Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)
Status:
Completed
Trial end date:
2019-10-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of multiple dose
administration of gefapixant (MK-7264) in participants with moderate to severe obstructive
sleep apnea (OSA). The primary hypothesis is that multiple dose administration of gefapixant
(MK-7264) in participants with moderate to severe OSA reduces the Apnea Hypopnea Index (AHI)
relative to placebo.